Parabolic Drugs Q3 revenue was up 29.8% at Rs 151.5 crore versus Rs 116.7 crore, YoY. Its PAT was up 33.2% at Rs 12.5 crore versus Rs 9.4 crore, YoY.
Its EBITDA margin was 20.9% versus 20.5%, YoY. The company's consumption of raw material was up 45.6% at Rs 124.6 crore versus Rs 85.6 crore, YoY.Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
